Pfizer (NYSE:PFE) reported positive Phase 3 MagnetisMM-32 results for ELREXFIO in relapsed or refractory multiple myeloma.

Pfizer Inc. PFE on Tuesday released topline results from its Phase 3 MagnetisMM-32 study evaluating Elrexfio (elranatamab) as ...

Pfizer’s Elrexfio has taken another step on its path to potential commercial momentum: The drugmaker just announced another ...

Based on reported profit, Pfizer stock costs more than the market. At the October 27, 2026 close, it traded at 39.2 times its ...

In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for ...

Pfizer has been going through a period of transition.

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...

The results showed that a four-dose regimen provoked immune responses against all 25 assessed serotypes.

Pfizer (PFE) on Tuesday announced a successful late-stage trial outcome for its multiple myeloma therapy, Elrexfio (elranatamab), when used in an earlier-line setting against the hematological cancer.

Pfizer’s Jeff Legos discusses how science, AI and patient insights are shaping cancer research and the next generation of ...

About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks ...

One of these pharma stocks offers more income, but the other offers a safer dividend.